Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Tatiana A. Ruzhentsova"'
Autor:
Pavel V. Chuchliaev, Maria V. Nikolskaya, Viktoria A. Razzhivina, Alexander A. Garbuzov, Daria A. Khavkina, Tatiana A. Ruzhentsova, Olga V. Filon
Publikováno v:
Èpidemiologiâ i Infekcionnye Bolezni. Aktual’nye voprosy. :38-44
Objective To provide evidence for the necessity and safety of using favipiravir for the treatment of adult patients with non-severe forms of COVID-19 Subjects and methods Of the 168 study participants, 163 received at least one dose of the test drug
Autor:
Marina G. Rusanova, Maria V. Otpushchennikova, Nataliya E. Kostina, Alexander A. Garbuzov, Antonina A. Ploskireva, Tatiana A. Ruzhentsova, Viсtoria S. Lesina, Moscow Jsc 'R-Pharm', Dmitriy A. Bistritskiy, Тatyana N. Markova, Viсtoria A. Razzhivina, Emilia N. Krasavina, Llc 'Mc Eco-safety', Alina S. Agaf'ina, Dzhavanshir M. Mustafaev, Tatyana N. Soluyanova, Rodion A. Oseshnyuk, Llc 'Neuroprofi', Yury F. Brook, Daria A. Khavkina, Olga V. Filon, Human Well-being Surveillance\\', Arkadiy V. Zintchenko, Oleg Yu. Bronov, Mikhail Yu. Samsonov, Konstantin A. Pokrovskiy, Tatiana N. Domostroeva, Adel Yu. Vafin, Sergey G. Shcherbak, Pavel V. Chukhlyaev, Elena P. Dmitrikova, Elena A. Kaplun, Evgeny I. Shults, Irina V. Shestakova, Diana V. Petina, Mariya V. Nikolskaya
Publikováno v:
Infectious diseases: News, Opinions, Training. 9:26-38
Material and methods An open-labeled, randomized, active-controlled multicenter trial of favipiravir in out- and hospitalized patients with mild to moderate COVID-19 was conducted Eligible patients were aged 18-60 years and had laboratory confirmed b